Jobevne Dosage

Generic name: BEVACIZUMAB 25mg in 1mL
Dosage form: injection
Drug class: VEGF/VEGFR inhibitors

Medically reviewed by Drugs.com. Last updated on Apr 1, 2025.

Important Administration Information

Withhold for at least 28 days prior to elective surgery. Do not administer Jobevne until at least 28 days following major surgery and until adequate wound healing.

Metastatic Colorectal Cancer

The recommended dosage when Jobevne is administered in combination with intravenous fluorouracil-based chemotherapy is:

•: 5 mg/kg intravenously every 2 weeks in combination with bolus-IFL.
•: 10 mg/kg intravenously every 2 weeks in combination with FOLFOX4.
•: 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks in combination with fluoropyrimidine-irinotecan-or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line bevacizumab product-containing regimen.

First-Line Non-Squamous Non-Small Cell Lung Cancer

The recommended dosage is 15 mg/kg intravenously every 3 weeks in combination with carboplatin and paclitaxel.

Recurrent Glioblastoma

The recommended dosage is 10 mg/kg intravenously every 2 weeks.

Metastatic Renal Cell Carcinoma

The recommended dosage is 10 mg/kg intravenously every 2 weeks in combination with interferon alfa.

Persistent, Recurrent, or Metastatic Cervical Cancer

The recommended dosage is 15 mg/kg intravenously every 3 weeks in combination with paclitaxel and cisplatin or in combination with paclitaxel and topotecan.

Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Stage III or IV Disease Following Initial Surgical Resection

The recommended dosage is 15 mg/kg intravenously every 3 weeks in combination with carboplatin and paclitaxel for up to 6 cycles, followed by Jobevne 15 mg/kg every 3 weeks as a single agent for a total of up to 22 cycles or until disease progression, whichever occurs earlier.

Recurrent Disease

Platinum Resistant

The recommended dosage is 10 mg/kg intravenously every 2 weeks in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan (every week).

The recommended dosage is 15 mg/kg intravenously every 3 weeks in combination with topotecan (every 3 weeks).

Platinum Sensitive

The recommended dosage is 15 mg/kg intravenously every 3 weeks, in combination with carboplatin and paclitaxel for 6 to 8 cycles, followed by Jobevne 15 mg/kg every 3 weeks as a single agent until disease progression.

The recommended dosage is 15 mg/kg intravenously every 3 weeks, in combination with carboplatin and gemcitabine for 6 to 10 cycles, followed by Jobevne 15 mg/kg every 3 weeks as a single agent until disease progression.

Dosage Modifications for Adverse Reactions

Table 1 describes dosage modifications for specific adverse reactions . No dose reductions for Jobevne are recommended.

Table 1: Dosage Modifications for Adverse Reactions
Adverse Reaction	Severity	Dosage Modification
Gastrointestinal Perforations and Fistulae.	• Gastrointestinal perforation, any grade • Tracheoesophageal fistula, any grade • Fistula, Grade 4 • Fistula formation involving any internal organ	Discontinue Jobevne
Wound Healing Complications.	• Any	Withhold Jobevne until adequate wound healing. The safety of resumption of bevacizumab products after resolution of wound healing complications has not been established
Wound Healing Complications.	• Necrotizing fasciitis	Discontinue Jobevne
Hemorrhage.	• Grade 3 or 4	Discontinue Jobevne
Hemorrhage.	• Recent history of hemoptysis of 1/2 teaspoon (2.5 mL) or more	Withhold Jobevne
Thromboembolic Events.	• Arterial thromboembolism, severe	Discontinue Jobevne
Thromboembolic Events.	• Venous thromboembolism, Grade 4	Discontinue Jobevne
Hypertension.	• Hypertensive crisis • Hypertensive encephalopathy	Discontinue Jobevne
Hypertension.	• Hypertension, severe (such as Grade 3 and above)	Withhold Jobevne until controlled with medical management; resume once controlled
Posterior Reversible Encephalopathy Syndrome (PRES).	• Any	Discontinue Jobevne
Renal Injury and Proteinuria.	• Nephrotic syndrome	Discontinue Jobevne
Renal Injury and Proteinuria.	• Proteinuria greater than or equal to 2 grams per 24 hours in absence of nephrotic syndrome	Withhold Jobevne until proteinuria less than 2 grams per 24 hours
Infusion-Related Reactions.	• Severe	Discontinue Jobevne
	• Clinically significant	Interrupt infusion; resume at a decreased rate of infusion after symptoms resolve
	• Mild, clinically insignificant	Decrease infusion rate
Congestive Heart Failure.	Any	Discontinue Jobevne

Preparation and Administration

Preparation

Use appropriate aseptic technique.
Use sterile needle and syringe to prepare Jobevne.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard vial if solution is cloudy, discolored or contains particulate matter.
Withdraw necessary amount of Jobevne and dilute in a total volume of 100 mL of 0.9% Sodium Chloride Injection, USP. DO NOT ADMINISTER OR MIX WITH DEXTROSE SOLUTION.
Discard any unused portion left in a vial, as the product contains no preservatives.
Diluted Jobevne solution may be stored at 2°C to 8°C (36°F to 46°F) for up to 8 hours, if not used immediately.
No incompatibilities between Jobevne and polyvinylchloride or polyolefin bags have been observed.

Administration

•: Administer as an intravenous infusion.
•: First infusion: Administer infusion over 90 minutes.
•: Subsequent infusions: Administer second infusion over 60 minutes if first infusion is tolerated. Administer all subsequent infusions over 30 minutes if second infusion over 60 minutes is tolerated.